The impact of the COVID-19 pandemic on treatment patterns in glioblastoma

Neuro Oncol. 2024 Mar 4;26(3):581-583. doi: 10.1093/neuonc/noad234.

Corey Neff^{1

2}, Mackenzie Price^{1

2}, Gino Cioffi^{1

3}, Kristin A Waite^{1

3}, Carol Kruchko¹, J Bryan Iorgulescu⁴, Jill S Barnholtz-Sloan^{1

3

5}, Quinn T Ostrom^{1

2

6}

¹ Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.
² Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina, USA.
³ Trans-Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, Maryland, USA.
⁴ Molecular Diagnostics Laboratory, Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁵ Center for Biomedical Informatics & Information Technology (CBIIT), National Cancer Institute, Bethesda, Maryland, USA.
⁶ The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina, USA.

No abstract available

Keywords: COVID-19; glioblastoma; treatment.

Publication types